Arrowhead Pharma (ARWR)

$63.82 +1.44 (2.31%)
Market Cap 8.94B
Revenue (ttm) 829.45M
Net Income (ttm) -1.63M
EPS (ttm) N/A
PE Ratio 40.77
Forward PE N/A
Profit Margin -0.20%
Debt to Equity Ratio 0.36
Volume 1,990,700
Avg Vol 3,200,794
Day's Range N/A - N/A
Shares Out 140.03M
Stochastic %K 22%
Beta 1.21
Analysts Strong Sell
Price Target $81.67

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
AbovetheGreenLine
AbovetheGreenLine Feb. 13 at 7:22 PM
Swing Trade Buy on the Close for Arrowhead Pharma $ARWR. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/u
0 · Reply
skeezbag
skeezbag Feb. 13 at 6:53 PM
$ARWR the magic wand was waved and found today's fake vwap
1 · Reply
skeezbag
skeezbag Feb. 13 at 4:31 PM
$ARWR babysitter still runs the house
0 · Reply
CDMO
CDMO Feb. 13 at 3:13 PM
$ARWR 64.5 EOD
0 · Reply
magross24
magross24 Feb. 13 at 2:04 AM
$ARWR are they taking this to $45 to protect the 4000 March calls?
0 · Reply
skeezbag
skeezbag Feb. 12 at 10:28 PM
$ARWR goldwoman sachs analyst going on paternal leave so the liars suspended coverage of all her/him/they/whatever coverage Not why the stock is moving AH cause the others aren't
1 · Reply
JFais
JFais Feb. 12 at 10:26 PM
$ARWR- another I sold too soon, but glad for longs. Set price alerts to revisit if comes down to my range Redemplo off to a good start, progress for core cardiovascular pipeline, intriguing (if unclear) early data for obesity & nice optionality in neurdegen + other tissue types
1 · Reply
Nasfact
Nasfact Feb. 12 at 9:54 PM
$ARWR sure make sense
2 · Reply
Nasfact
Nasfact Feb. 12 at 9:19 PM
#1 $SLS #2 $GME #3 $NVAX #4 $BYND #5 $ARWR What do they have in common? Except market manipulation and that ...I own them all...? Patience is the key! My opinion
2 · Reply
skeezbag
skeezbag Feb. 12 at 8:58 PM
$ARWR yay found vwap! Fucking fake market
0 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript

Feb 6, 2026, 12:34 AM EST - 11 days ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Feb 5, 2026, 4:05 PM EST - 11 days ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Feb 4, 2026, 6:15 PM EST - 12 days ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT CIEN DAY DVAX OSW

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 27, 2026, 7:30 AM EST - 20 days ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 20, 2026, 4:30 PM EST - 27 days ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:06 PM EST - 5 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 11:05 PM EST - 5 weeks ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 7, 2026, 7:30 AM EST - 5 weeks ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 6:14 PM EST - 5 weeks ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Jan 6, 2026, 3:18 PM EST - 5 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 6, 2026, 2:58 PM EST - 5 weeks ago

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 11:26 AM EST - 5 weeks ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Jan 6, 2026, 10:32 AM EST - 5 weeks ago

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 6, 2026, 7:30 AM EST - 5 weeks ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Jan 5, 2026, 7:30 AM EST - 6 weeks ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 23, 2025, 7:30 AM EST - 7 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 15, 2025, 4:30 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 8, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 2, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Dec 1, 2025, 4:00 PM EST - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Nov 27, 2025, 7:43 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 11:43 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 25, 2025, 4:00 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Nov 19, 2025, 3:48 AM EST - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Nov 18, 2025, 11:54 PM EST - 3 months ago

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:52 AM EST - 3 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

US FDA approves Arrowhead's genetic disorder drug

Nov 18, 2025, 11:21 AM EST - 3 months ago

US FDA approves Arrowhead's genetic disorder drug

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Nov 17, 2025, 10:08 AM EST - 3 months ago

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 6, 2025, 4:30 PM EST - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Nov 4, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 21, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 5 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 11, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:55 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 10, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:42 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:35 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Sep 3, 2025, 4:00 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Sep 3, 2025, 1:15 PM EDT - 5 months ago

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025, 8:13 AM EDT - 5 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 8, 2025, 8:48 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 7 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

AbovetheGreenLine
AbovetheGreenLine Feb. 13 at 7:22 PM
Swing Trade Buy on the Close for Arrowhead Pharma $ARWR. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/u
0 · Reply
skeezbag
skeezbag Feb. 13 at 6:53 PM
$ARWR the magic wand was waved and found today's fake vwap
1 · Reply
skeezbag
skeezbag Feb. 13 at 4:31 PM
$ARWR babysitter still runs the house
0 · Reply
CDMO
CDMO Feb. 13 at 3:13 PM
$ARWR 64.5 EOD
0 · Reply
magross24
magross24 Feb. 13 at 2:04 AM
$ARWR are they taking this to $45 to protect the 4000 March calls?
0 · Reply
skeezbag
skeezbag Feb. 12 at 10:28 PM
$ARWR goldwoman sachs analyst going on paternal leave so the liars suspended coverage of all her/him/they/whatever coverage Not why the stock is moving AH cause the others aren't
1 · Reply
JFais
JFais Feb. 12 at 10:26 PM
$ARWR- another I sold too soon, but glad for longs. Set price alerts to revisit if comes down to my range Redemplo off to a good start, progress for core cardiovascular pipeline, intriguing (if unclear) early data for obesity & nice optionality in neurdegen + other tissue types
1 · Reply
Nasfact
Nasfact Feb. 12 at 9:54 PM
$ARWR sure make sense
2 · Reply
Nasfact
Nasfact Feb. 12 at 9:19 PM
#1 $SLS #2 $GME #3 $NVAX #4 $BYND #5 $ARWR What do they have in common? Except market manipulation and that ...I own them all...? Patience is the key! My opinion
2 · Reply
skeezbag
skeezbag Feb. 12 at 8:58 PM
$ARWR yay found vwap! Fucking fake market
0 · Reply
CDMO
CDMO Feb. 12 at 8:39 PM
$ARWR hello, my name is bill
0 · Reply
Jschwarma
Jschwarma Feb. 12 at 6:09 PM
$ARWR Blackrock with anither 1,093,000 bringing total to 21.3M shares (16%) seems like they have conviction?
2 · Reply
skeezbag
skeezbag Feb. 12 at 5:24 PM
$ARWR gotta keep vwap at 62 just like yesterday keeping vwap at 61.55
0 · Reply
skeezbag
skeezbag Feb. 12 at 4:40 PM
$ARWR previous fake floor is now the new fake ceiling to all the Bills
0 · Reply
jancula
jancula Feb. 12 at 4:33 PM
$ARWR should buy $SRPT at these levels. Can double their revenues by replacing Elevidys and DMOs by their siRNA stuff
1 · Reply
ZoeyTanner
ZoeyTanner Feb. 12 at 11:05 AM
$ARWR Lower lows, lower highs day after day..no white knight, no savior..death spiral?
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 10:24 AM
$ARWR RSI: 32.98, MACD: -0.3463 Vol: 3.01, MA20: 66.64, MA50: 66.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Martinsucks
Martinsucks Feb. 11 at 9:10 PM
$ARWR can't believe people on this board complain when this was at 20 in September. Try holding Srpt. 🤡 S
1 · Reply
skeezbag
skeezbag Feb. 11 at 8:51 PM
$ARWR poof magic, time to go find vwap
0 · Reply
The_Free_Trader
The_Free_Trader Feb. 11 at 7:17 PM
$SRPT $ARWR That’s the disconnect. The market’s acting like we already know the Arrowhead assets don’t work, when we literally haven’t seen the data yet. With no debt overhang and core assets still intact, $17 feels more like fear pricing than fair value
3 · Reply
skeezbag
skeezbag Feb. 11 at 7:17 PM
$ARWR 62 was the fake floor now it needs to look like the fake ceiling
0 · Reply
Pharmer23
Pharmer23 Feb. 11 at 6:49 PM
$SRPT Nov 2024 is when thy signed the deal with $ARWR, since then they have paid out $1.125 BILLION in payments for that pipeline . 2026 is when we will see what exactly we have bought and the potential of these assets . Dont be a fool and think this is worth anything close to 17 bucks a share .that doesn’t include Elevidys and PMOS and no debt overhang till 2030 .
0 · Reply